ASCO GI Highlights

A US real-world claims database analysis demonstrated that durvalumab plus gemcitabine and cisplatin improves survival in patients with advanced biliary tract cancer.

Real‑world outcomes show survival benefit of first-line durvalumab or pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Tinengotinib, a novel FGFR inhibitor, has the potential to overcome resistance to prior FGFR therapies in the treatment of advanced cholangiocarcinoma.

FGFR2 inhibition with lirafugratinib delivers strong responses and manageable safety in FGFR2‑altered advanced cholangiocarcinoma.

A post-hoc analysis of HERIZON-BTC-01 demonstrates improved survival outcomes in patients utilizing zanidatamab.

Ivosidenib in combination with durvalumab plus gemcitabine and cisplatin shows potential activity with minimal toxicity in patients with IDH1‑mutant cholangiocarcinoma.

Real‑world data in IDH1‑mutant cholangiocarcinoma illuminates biomarker testing trends, treatment sequencing, and survival outcomes, outlining the role of ivosidenib in second‑line care.

Adjuvant sintilimab plus capecitabine shows promising recurrence‑free survival and manageable safety in resected extrahepatic cholangiocarcinoma.

The ACCORD trial demonstrated that adjuvant chemoradiation combined with immunotherapy significantly improved survival outcomes in patients with resectable extrahepatic cholangiocarcinoma and gallbladder cancer compared with observation alone.

A study of patients with advanced biliary tract cancer found that adding lenvatinib to durvalumab and gemcitabine-based chemotherapy improved progression-free survival, objective response rate, and disease control rate.